Patients with active HCV infection should be referred for HCV treatment and standard radiotherapy for the plasmacytoma
History of hepatitis C (HCV) with HCV RNA positivity within  months prior to the date of informed consent for this study (if no test has been performed within  months it must be done at screening);
Participants known to be human immunodeficiency virus (HIV)-positive or known to have active hepatitis B or C; Note: Participants in whom hepatitis C virus (HCV) infection resolved spontaneously (positive HCV antibodies without detectable HCV-ribonucleic acid [RNA]) or those that achieved a sustained virological response after antiviral treatment and show absence of detectable HCV RNA >=  months (with the use of IFN-based regimens) after cessation of antiviral treatment are eligible
Active hepatitis C subjects as demonstrated by test for hepatitis C ribonucleic acid (RNA). Subjects who are HCV antibody positive will be screened for HCV RNA by any RT-PCR or by DNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value.
Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.
Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA)
Known to be seropositive for hepatitis C (anti-HCV antibody positive or HCV-RNA quantitation positive) except in the setting of a sustained virologic response [SVR], defined as aviremia at least  weeks after completion of antiviral therapy
Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test at screening confirmed by a polymerase chain reaction (PCR) positive for HCV RNA.
Active hepatitis C (HCV) infection without treatment is permitted; concomitant treatment of HCV is not permitted on this study
Subjects with chronic infection by hepatitis C virus (HCV) who are untreated or who failed previous therapies for HCV are allowed on study; in addition, subjects with successful HCV treatment (defined as sustained virologic response [SVR]  or SVR ) are allowed as long as  weeks have passed between completion of HCV therapy and start of study drug
Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA) by quantitative PCR.
Active replication of hepatitis B or active hepatitis C (hepatitis C virus [HCV] ribonucleic acid [RNA] positive); those with prior disease who are PCR negative at enrollment and meet liver function eligibility criterion are eligible
Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening.
Patients with known active hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection:\r\n* Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or cytomegalovirus (CMV) as defined below\r\n* Positive serology for HIV\r\n* Active hepatitis B infection as determined by a positive test for hepatitis B surface antigen (Ag)\r\n* Active hepatitis C; patients will be screened for HCV antibody; if the HCV antibody is positive, a screening HCV ribonucleic acid (RNA) by any reverse transcriptase polymerase chain reaction (RT PCR) or branched deoxyribose nucleic acid (bDNA) assay must be performed at screening by a local laboratory with a Clinical Laboratory Improvement Act (CLIA) certification or its equivalent; eligibility will be determined based on a negative screening value; the test is not required if documentation of a negative result of a HCV RNA test performed within  days prior to screening is provided\r\n* Serology (CMV immunoglobulin G [IgG]) positive for active CMV
Subjects who have received therapy for HCV =<  weeks from the start of pembrolizumab; Note: those with untreated HCV and those who completed HCV therapy >=  weeks of study treatment start are eligible
Hepatitis C virus (HCV) antibody positive and detectable HCV quantitative ribonucleic acid (RNA), with clinical evidence of cirrhosis as determined by the principal investigator
Evidence of active hepatitis C (HCV); subjects with positive hepatitis C serology and positive HCV ribonucleic acid (RNA) test
known active hepatitis C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RA;
Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing); patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
Participant must have the following indicator- of chronic hepatitis C virus infection prior to study enrollment:  Positive for HCV RNA at the time of screening
Patients with positive test for hepatitis C ribonucleic acid (HCV RNA)
Patients with chronic HCV infection with less than  weeks between completion of HCV therapy and start of study drug. Note: patients with chronic infection with HCV who are untreated or noncuratively treated HCV are allowed on study.
Hepatitis C virus (HCV): negative viral ribonucleic acid (RNA) (if HCV antibody is positive)
Active hepatitis C\r\n* Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV ribonucleic acid (RNA)
Hepatitis C virus (HCV) antibody positive and detectable HCV quantitative ribonucleic acid (RNA) with clinical evidence of cirrhosis
Serum HCV ribonucleic acid (RNA) levels of > , IU per milliliter or higher
HCV genotype , , , 
Participants with chronic infection by Hepatitis C Virus (HCV) who are treated (successfully or treatment failure) or untreated are allowed on study. In addition, participants with successful HCV treatment are allowed as long as there are > weeks between achieving sustained viral response (SVR) and start of study drug.
Participants with past or resolved hepatitis B virus (HBV) infection are eligible; participants positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV Riboxy Nucleic Acid (RNA).
Uncontrolled hepatitis C virus (HCV) infection, defined as plasma HCV RNA detectable by PCR\r\n* Note: the following will NOT be exclusionary:\r\n** Positive HCV serology but no detectable HCV RNA, indicative of spontaneously cleared HCV infection\r\n** Patients who have been successfully treated for HCV as long as therapy for HCV has been completed
Active hepatitis C infection as determined by hepatitis C RNA; A subject who is HCV antibody positive will be screened for HCV RNA by any RT polymerase chain reaction (PCR) or bDNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value.
Except in cohort , HPV-associated cancers active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test followed by a positive HCV RNA test at screening; the HCV RNA test will be performed only for patients who have a positive HCV antibody test
Hepatitis C virus (HCV) antibody positive with HCV RNA positive
Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA) by quantitative PCR
Patients must be screened for HCV. Patients must have negative hepatitis C antibody (HCV Ab) or are HCV Ab positive but with an undetectable level of HCV-RNA. Note: patients with detectable HCV-RNA are not eligible for the study.
Known hepatitis C virus (HCV) positive with chronic HCV or active viral infection with HCV hepatitis requiring anti-viral medication (at time of randomization).
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
Hepatitis C virus (HCV): patients with positive hepatitis C serology unless HCV ribonucleic acid (RNA) is confirmed negative and may be considered for inclusion in the study on a case-by-case basis
For patients with unknown hepatitis C virus ribonucleic acid (HCV antibody) status, must be tested during study screening; patients who are tested positive for HCV antibody are excluded from the study if they have inadequately controlled hepatitis C and/or Child-Pugh Class B or C cirrhosis; patients with adequately controlled hepatitis are not excluded from the study as defined by having undetectable level of serum HCV antibody level prior to enrollment; patients who are currently on interferon or other anti-HCV therapy will be excluded from study
Evidence of active hepatitis C (hepatitis C virus [HCV]): subjects with positive hepatitis C serology AND positive HCV ribonucleic acid (RNA) test
Active hepatitis C. Patients will be screened for HCV antibody. If the HCV antibody is positive, a screening HCV RNA by any RT PCR or bDNA assay must be performed at screening by a local laboratory with a CLIA certification or its equivalent. Eligibility will be determined based on a negative screening value. The test is not required if documentation of a negative result of a HCV RNA test performed within  days prior to screening is provided.
Detectable HCV RNA with anti-HCV-positivity
Patients with undetectable HCV RNA
Active Hepatitis C. Patients will be screened for HCV antibody. If the HCV antibody is positive, a screening HCV RNA by any RT-PCR or bDNA assay must be performed at screening by a local laboratory with a CLIA certification or its equivalent. Eligibility will be determined based on a negative screening value. The test is not required if documentation of a negative result of a HCV RNA test performed within  days prior to screening is provided.
Participants positive for Hepatitis C virus (HCV) antibody were eligible only if polymerase chain reaction(PCR) was negative for HCV Ribonucleic acid (RNA)
Hepatitis B or C (HBsAg in the absences or HBsAB or HCV Ab positive with HCV RNA positive)
Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
DONOR: Positive anti-hepatitis C (HCV) antibodies and a positive serum HCV RNA PCR; all positive HCV antibody results must be assessed by an enzyme-linked immunosorbent assay (EIA) assay and confirmed by a quantitative serum HCV RNA assay; participants with positive HCV antibodies but undetectable serum HCV ribonucleic acid (RNA) may be considered for eligibility; participants with negative anti-HCV antibodies but unexplained liver enzyme abnormalities must undergo a quantitative serum RNA assay to rule out false negative HCV serologies
Participants who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation
Positive anti-hepatitis C (HCV) antibodies and a positive serum HCV ribonucleic acid (RNA) PCR; all positive HCV antibody results must be assessed by an enzyme immunoassay (EIA) assay and confirmed by a quantitative serum HCV RNA assay; participants with positive HCV antibodies but undetectable serum HCV RNA may be considered for eligibility; participants with negative anti-HCV antibodies but unexplained liver enzyme abnormalities must undergo a quantitative serum RNA assay to rule out false negative HCV serologies
DONOR: Positive anti-hepatitis C (HCV) antibodies and a positive serum HCV RNA PCR; all positive HCV antibody results must be assessed by an EIA assay and confirmed by a quantitative serum HCV RNA assay; participants with positive HCV antibodies but undetectable serum HCV RNA may be considered for eligibility; participants with negative anti-HCV antibodies but unexplained liver enzyme abnormalities must undergo a quantitative serum RNA assay to rule out false negative HCV serologies
Presence of hepatitis C antibody test (anti-HCV)
Active hepatitis C virus (HCV); patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
Active hepatitis C infection as demonstrated by test for hepatitis C RNA. Subjects who are HCV antibody positive will be screened for HCV RNA by any RT PCR or bDNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value.
Positive hepatitis C antibody and positive confirmatory hepatitis C virus (HCV) ribonucleic acid (RNA) test; the confirmatory HCV RNA test is not required if the HCV antibody is negative; if hepatitis C antibody is positive, the confirmatory HCV RNA test should be done and if it is negative, then participants are eligible
Presence of chronic HCV infection; note: chronic HCV infection is defined by () presence of plasma or serum HCV RNA in a participant with HCV antibody for >=  days, or () two documented HCV RNA positive results >=  days apart, OR () positive HCV RNA with biopsy demonstrating chronic hepatitis
subjects with resolved or treated HCV (i.e. HCV antibody positive but undetectable HCV RNA)
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA
Positive test for human immunodeficiency virus (HIV) or hepatitis C (HCV) antibodies (unless HCV viral load test by PCR is negative)